Nuvectis Pharma to Present New Clinical Data on NXP900 SRC/YES1 Kinase Inhibitor at 2025 AACR-NCI-EORTC Conference

Reuters

2025/10/16

<a href="https://laohu8.com/S/NVCT">Nuvectis Pharma</a> to Present New Clinical Data on NXP900 SRC/YES1 Kinase Inhibitor at 2025 AACR-NCI-EORTC Conference

Nuvectis Pharma Inc., a clinical stage biopharmaceutical company, has announced upcoming poster presentations for its investigational SRC/YES1 kinase inhibitor, NXP900, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The presentations will cover clinical safety, pharmacokinetics, pharmacodynamics, and cytochrome P450 interactions of NXP900, as well as its efficacy in inhibiting tumor growth in FAT1 mutated xenograft models. The results will be presented on October 23, 2025, in Boston, Massachusetts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvectis Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9546459-en) on October 16, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2575374553"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575374553\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575374553?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-16 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575374553","market":"us","top_or_hot":-1,"title":"Nuvectis Pharma to Present New Clinical Data on NXP900 SRC/YES1 Kinase Inhibitor at 2025 AACR-NCI-EORTC Conference","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NVCT\">Nuvectis Pharma</a> to Present New Clinical Data on NXP900 SRC/YES1 Kinase Inhibitor at 2025 AACR-NCI-EORTC Conference\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Nuvectis Pharma Inc., a clinical stage biopharmaceutical company, has announced upcoming poster presentations for its investigational SRC/YES1 kinase inhibitor, NXP900, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. The presentations will cover clinical safety, pharmacokinetics, pharmacodynamics, and cytochrome P450 interactions of NXP900, as well as its efficacy in inhibiting tumor growth in FAT1 mutated xenograft models. The results will be presented on October 23, 2025, in Boston, Massachusetts.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvectis Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9546459-en) on October 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nuvectis Pharma to Present New Clinical Data on NXP900 SRC/YES1 Kinase Inhibitor at 2025 AACR-NCI-EORTC Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNuvectis Pharma to Present New Clinical Data on NXP900 SRC/YES1 Kinase Inhibitor at 2025 AACR-NCI-EORTC Conference\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-16 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NVCT\">Nuvectis Pharma</a> to Present New Clinical Data on NXP900 SRC/YES1 Kinase Inhibitor at 2025 AACR-NCI-EORTC Conference\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Nuvectis Pharma Inc., a clinical stage biopharmaceutical company, has announced upcoming poster presentations for its investigational SRC/YES1 kinase inhibitor, NXP900, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. The presentations will cover clinical safety, pharmacokinetics, pharmacodynamics, and cytochrome P450 interactions of NXP900, as well as its efficacy in inhibiting tumor growth in FAT1 mutated xenograft models. The results will be presented on October 23, 2025, in Boston, Massachusetts.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvectis Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9546459-en) on October 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nNDL3vPf2j:1","article_id":"2575374553","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575374553","pubTimestamp":1760616042,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nuvectis Pharma Inc., a clinical stage biopharmaceutical company, has announced upcoming poster presentations for its investigational SRC/YES1 kinase inhibitor, NXP900, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The presentations will cover clinical safety, pharmacokinetics, pharmacodynamics, and cytochrome P450 interactions of NXP900, as well as its efficacy in inhibiting tumor growth in FAT1 mutated xenograft models. The results will be presented on October 23, 2025, in Boston, Massachusetts.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvectis Pharma Inc. published the original content used to generate this news brief via GlobeNewswire  on October 16, 2025, and is solely resp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","NVCT":"Nuvectis Pharma, Inc.","BK4139":"生物科技","NDAQ":"纳斯达克OMX交易所","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC"},"translate_title":"Nuvectis Pharma将在2025年AACR-NCI-EORTC会议上展示NXP900 SRC/YES1激酶抑制剂的新临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVCT":0.9,"NDAQ":0.9},"content_text":"Nuvectis Pharma to Present New Clinical Data on NXP900 SRC/YES1 Kinase Inhibitor at 2025 AACR-NCI-EORTC Conference\n    \n\n        Nuvectis Pharma Inc., a clinical stage biopharmaceutical company, has announced upcoming poster presentations for its investigational SRC/YES1 kinase inhibitor, NXP900, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The presentations will cover clinical safety, pharmacokinetics, pharmacodynamics, and cytochrome P450 interactions of NXP900, as well as its efficacy in inhibiting tumor growth in FAT1 mutated xenograft models. The results will be presented on October 23, 2025, in Boston, Massachusetts.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvectis Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9546459-en) on October 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}